WMT

119.41

+1.16%↑

COST

984.37

+2.05%↑

TGT

106.46

-2.41%↓

64.17

+1.81%↑

DG.US

147.16

+0.75%↑

WMT

119.41

+1.16%↑

COST

984.37

+2.05%↑

TGT

106.46

-2.41%↓

64.17

+1.81%↑

DG.US

147.16

+0.75%↑

WMT

119.41

+1.16%↑

COST

984.37

+2.05%↑

TGT

106.46

-2.41%↓

64.17

+1.81%↑

DG.US

147.16

+0.75%↑

WMT

119.41

+1.16%↑

COST

984.37

+2.05%↑

TGT

106.46

-2.41%↓

64.17

+1.81%↑

DG.US

147.16

+0.75%↑

WMT

119.41

+1.16%↑

COST

984.37

+2.05%↑

TGT

106.46

-2.41%↓

64.17

+1.81%↑

DG.US

147.16

+0.75%↑

Home・Akcijų sąrašas・USANA Health Sciences Inc

USANA Health Sciences Inc

Atidarymo kaina

22 0.23

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21.66

Max

22.5

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-17M -6.7M
Pardavimai	-22M 214M
P/E Sektoriaus vid.	22.889 28.875
Pelnas, tenkantis vienai akcijai	-0.15
Pelno marža	-3.118
Darbuotojai	1,700
EBITDA	-17M 11M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	+77.51% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-24

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-5.1M 377M
Ankstesnė atidarymo kaina	21.77
Ankstesnė uždarymo kaina	22

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

28.405 / 29.84 Palaikymas ir pasipriešinimas

USANA Health Sciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-20 23:43; UTC

Rinkos pokalbiai

Gold Consolidates; May Face Technical Correction -- Market Talk

2026-01-20 23:42; UTC

Rinkos pokalbiai

Nikkei May Fall Amid Concerns Over U.S.-Europe Trade Relations -- Market Talk

2026-01-20 23:41; UTC

Uždarbis

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- 2nd Update

2026-01-20 23:29; UTC

Rinkos pokalbiai

RBA Rate Hike in February Would Be a Painful One -- Market Talk

2026-01-20 23:26; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-20 23:26; UTC

Rinkos pokalbiai

James Hardie Appeals More as Reece's U.S. Strategy Comes Under Scrutiny -- Market Talk

2026-01-20 22:45; UTC

Įsigijimai, susijungimai, perėmimai

ACCC: Ampol-EG Deal Is First Assessment Subject to Phase 2 Review Under New Merger Control Regime

2026-01-20 22:45; UTC

Įsigijimai, susijungimai, perėmimai

ACCC Seeks Submissions in Response to Phase 2 Notice by February 4

2026-01-20 22:44; UTC

Įsigijimai, susijungimai, perėmimai

ACCC: Ampol's Offer to Sell 19 Retail Fuel Sites Doesn't Adequately Address Issues

2026-01-20 22:44; UTC

Įsigijimai, susijungimai, perėmimai

ACCC Identifies 115 EG Sites Where Deal Could Substantially Lessen Competition

2026-01-20 22:43; UTC

Įsigijimai, susijungimai, perėmimai

ACCC Says Deal Could Substantially Lessen Competition in Retail Supply of Petrol, Diesel in Several Markets in Australia

2026-01-20 22:43; UTC

Įsigijimai, susijungimai, perėmimai

Ampol's Acquisition of EG Australia to Undergo In-Depth Review by Competition Regulator

2026-01-20 22:27; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Plans to Roll Out New Mobile User Interface Later This Year, Co-CEO Says

2026-01-20 22:25; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Co-CEO Sees Uptick in Engagement for TV-Based Games

2026-01-20 22:21; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Would Keep 45-Day Theater Release Window for Warner Bros. Films, Co-CEO Says

2026-01-20 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Excited to Strengthen Warner Bros.'s Theatrical-Distribution Business, Co-CEO Says

2026-01-20 22:19; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Pleased With Early Results for Podcasts, Co-CEO Says

2026-01-20 22:18; UTC

Uždarbis

Netflix Stock Is Falling. This Is Overshadowing the Streamer's Earnings Beat. -- Barrons.com

2026-01-20 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Netflix's Live Events Are Boosting Retention, Co-CEO Says

2026-01-20 22:16; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Remains 'Very Excited' About Live-Events Offering, Co-CEO Says

2026-01-20 22:15; UTC

Įsigijimai, susijungimai, perėmimai

Netflix's Proposed Deal for Warner Bros. Would Protect, Create Jobs, Co-CEO Says

2026-01-20 22:15; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Competes for Attention Across Streaming, Broadcast, Cable, Gaming, Social Media, Video Platforms, Co-CEO Says

2026-01-20 22:13; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Co-CEO: TV Landscape Has Never Been More Competitive

2026-01-20 22:11; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Confident Warner Bros. Deal Would Pass Regulatory Review, Co-CEO Says

2026-01-20 22:10; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Would Leverage Global Footprint, Streaming Expertise to Improve Warner Bros.'s HBO Max Service, Co-CEO Says

2026-01-20 22:08; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Won't Raise Prices During Regulatory-Review Process for Pending Warner Bros. Deal, Co-CEO Says

2026-01-20 22:07; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Sees Warner Bros. as Another Mechanism to Improve Offerings, Co-CEO Says

2026-01-20 22:06; UTC

Uždarbis

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- Update

2026-01-20 22:00; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

ESG Roundup: Market Talk

2026-01-20 21:50; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

USANA Health Sciences Inc Prognozė

Kainos tikslas

By TipRanks

77.51% į viršų

12 mėnesių prognozė

Vidutinis 39 USD 77.51%

Aukščiausias 39 USD

Žemiausias 39 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines USANA Health Sciences Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių USANA Health Sciences Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

28.405 / 29.84Palaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There are no events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę USANA Health Sciences Inc

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products through retail stores and online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.